Stereotaxis Inc. (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has reported its financial results for the second quarter ended June 30, 2025. The company recorded an operating loss of $4.0 million and a net loss of $3.8 million for the quarter, showing improvement from the previous year's losses of $6.0 million and $5.8 million, respectively. Adjusted operating loss and adjusted net loss, excluding non-cash charges, were $1.4 million and $1.3 million, respectively, compared to $3.5 million and $3.3 million in the previous year. The company's cash and cash equivalents stood at $7.0 million with no debt as of June 30, 2025. In July, Stereotaxis raised $12.5 million in a registered direct financing, with $8.5 million received by the end of that month, leading to a proforma cash balance of $18.8 million. Stereotaxis has reiterated its expectation of double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue expected to scale to $7 million by the fourth quarter. The company anticipates substantial growth in 2026, following anticipated regulatory milestones and initial commercial launches in 2025.